tbuckley/cabot-search huggingface dataset:
Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma.
Authors: P W Johnson, C G Price, T Smith, F E Cotter, J Meerabux, A Z Rohatiner, B D Young, T A Lister
Journal: Journal of Clinical Oncology (1994)

PURPOSE To use the polymerase chain reaction (PCR) technique for molecular assessment of the results of myeloablative treatment of follicular lymphoma with autologous bone marrow transplantation. PATIENTS AND METHODS Seventy-six patients with follicular or transformed follicular lymphoma were treated with cyclophosphamide 60 mg/kg x 2 and total-body irradiation 12 Gy, supported by autologous bone marrow transplantation. The bone marrow mononuclear cell fraction was treated in vitro with CD20 monoclonal antibody and baby rabbit complement. The PCR technique was used to identify 50 patients with amplifiable t(14; 18) translocations in biopsy material from lymph nodes or bone marrow infiltrated by lymphoma. RESULTS Following treatment of the harvested bone marrow in vitro, 29 samples were tested by PCR to assess the efficacy of purging. In 25 cases, the same t(14; 18) sequences were amplified as from the patients' original biopsies, while in four cases, the marrow became PCR-negative. Three of the four patients treated with PCR-negative marrow subsequently developed recurrent lymphoma, compared with 11 of 25 in the PCR-positive group. Bone marrow and peripheral-blood mononuclear cell samples from 27 patients were studied during the follow-up period. All but one had the presence of the lymphoma-related t(14; 18) clone detectable by PCR and confirmed by direct sequencing from at least one sample between 3 months and 7 years after reinfusion of the bone marrow. With a median follow-up duration of 3 years, 13 patients developed recurrent disease, 13 remained in remission with the t(14; 18) still detectable, and one died of acute myeloid leukemia. CONCLUSION This form of therapy does not eliminate the lymphoma-related t(14; 18)-bearing clone of cells, although the significance of its continued presence is uncertain. Improved methods for both treatment of the bone marrow in vitro and treatment of the lymphoma in vivo are required.
Demographics, clinical profile, management, and outcome of retinoblastoma in a tertiary care center in southern India
Authors: V. P. Reddy, S. G. Honavar, D. Shome, K. Shah, M. N. Naik, R. Rao
Journal: Journal of Clinical Oncology (2007)

20011 Background: Retinoblastoma is the most common malignant intraocular tumor in children. The estimated incidence of retinoblastoma in India is about 2,000 a year. However, there is scant data on the clinical manifestations and outcome of retinoblastoma in India. Methods: In this retrospective case series, the medical records of 460 consecutive cases of retinoblastoma from January 1990 to December 2004 were analyzed for demographics, clinical profile, treatment and outcome (survival, organ and function salvage). Results: An integrated Ocular Oncology Service was established at the treatment center in the year 2000 and a specialized Children’s Eye Cancer Center was founded in 2004. The annual referral increased from &lt;20 a year before 2000 to 38 in 2000, and 120 in 2005. Two hundred and six (45%) patients were economically underprivileged. A majority (303, 66%) presented &lt;3 years of age. There were 277 (60%) males. Although 188 (41%) were bilateral, family history was forthcoming in only 19 (4%). Of 648 involved eyes, 531 (82%) eyes were symptomatic. Leucocoria (71%) was the most common symptom, followed by visual loss (12%), eyelid edema or proptosis (7%), squint (6%), pain (2%), redness (2%), enlarged eyeball (2%), or shrunken eyeball (1%). The tumor was intraocular in 609 (94%) eyes while 39 (6%) were extraocular. Enucleation was the most common primary treatment for intraocular retinoblastoma (236 of 451, 52%), followed by chemoreduction coupled with focal therapy (26%), focal therapy alone (11%), external beam radiation (55) or chemotherapy alone (4%). Histopathologic risk factors predictive of metastasis were found in 152 of 277 (55%) eyes that underwent enucleation. Chemoreduction with focal therapy resulted in eye and vision salvage in 109 of 118 (92%). At the final follow-up (minimum 24 months), 434 (94%) were alive and well. Conclusions: Retinoblastoma has excellent prognosis for survival, eye salvage and vision salvage with the current management modalities. An integrated approach involving a team of a pediatric oncologist and an ocular oncologist at a comprehensive tertiary care center may augment referrals and help implement systematic treatment strategies. No significant financial relationships to disclose.
Selective alpha v integrin deletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs
Authors: Neil C. Henderson, Thomas Arnold, Yoshio Katamura, Marilyn Giacomini, Juan Rodriguez, Joseph McCarty, Peter Ruminski, David Griggs, Jacquelyn J. Maher, John P. Iredale, Adam Lacy-Hulbert, Ralf H. Adams, Dean Sheppard
Journal: Hepatology (2012)
The Ep-CAM: A potential candidate for diagnosis in ovarian cancer
Authors: T. Sawasaki, Y. Katsube
Journal: Journal of Clinical Oncology (2009)

e16571 Background: The purpose of this study was to examine the expression of splice variants of the Ep-CAM gene in normal ovarian epithelial tissue and ovarian carcinoma and further to associate the expression of Ep-CAM with clinicopathologic characteristics if such an association exists. Methods: Ep-CAM expression was examined by semiquantitative PCR in 122 ovarian tumors (92 adenocarcinomas, 10 low malignant potential (LMP) tumors, and 10 adenomas) and 10 normal ovaries. Results: In carcinomas as well as LMP tumors and adenomas, Ep-CAM mRNA expression was significantly elevated compared to that in normal ovary samples. Ep-CAM mRNA expression level in carcinomas was significantly elevated compared to that in adenomas and Ep-CAM mRNA expression level in advanced clinical stage diseases was significantly higher than that in early stage diseases in ovarian carcinomas. With regard to histological type, Ep-CAM mRNA expression level in mucinous adenocarcinomas was significantly higher than those in the other tissue subtypes. Conclusions: These features imply that Ep-CAM expression may play an important role in ovarian cancer development and progression, and this may be useful as a diagnostic marker. No significant financial relationships to disclose.
Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease : Results From TRACER
Authors: Schuyler Jones, Pierluigi Tricoci, Zhen Huang, David J. Moliterno, Robert A. Harrington, Peter Sinnaeve, John Strony, Frans Van de Werf, Harvey D. White, Claes Held, Paul W. Armstrong, Philip E. Aylward, Edmond Chen, Manesh R. Patel, Kenneth W. Mahaffey
Journal: Circulation (2013)

Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease : Results From TRACER
A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.
Authors: Pradyumna D. Phatak, Pierre Brissot, Herbert Bonkovsky, Mark Wurster, Lawrie Powell, Claus Niederau, Paul Adams, Wolfgang Stremmel, Louis Griffel, Nicola Lynch, Oliver Schoenborn-Kellenberger, Antonello Pietrangelo
Journal: Blood (2009)
A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC)
Authors: C. Boni, T. Gamucci, A. Bonetti, G. Bisagni, E. Dall'o', C. Zanna, S. Marsoni, C. Sessa
Journal: Journal of Clinical Oncology (2004)

3684 Background: Gimatecan (ST1481) is a new, orally available camptothecin with a favorable therapeutic index in preclinical tumor models. Myelosuppression was the main toxicity during the initial phase I study which concurrently evaluated oral (po) dosing on a daily times five schedule for 1, 2, or 3 weeks every 28 days. The recommended phase II dose for the 2 weeks schedule was defined at 5.6 mg/m2 since none of 9 CRC patients tested experienced grade 3 toxicities. Methods: A phase II study with a Simon 2-Step design was initiated in June 2003 to assess the activity of the dx5x2 week schedule in patients with metastatic colorectal cancer. Response and toxicity were the primary and secondary endpoints, respectively. The original dose of 5.6 mg/m2 q 28 days was reduced to 5.0 mg/m2 after the occurrence of a prolonged pancytopenia and death at cycle one. Results: Since June 2003, 18 patients with metastatic CRC have been treated with Gimatecan: 9 at 5.6 mg/m2, and 9 at the reduced dose of 5.0 mg/m2. Ten (55.5%) were male and the median age was 61 (range 35–72 years). Nine patients had received one prior regimen of chemotherapy and nine had received 2 prior regimens for metastatic disease, containing Irinotecan in 50% of cases - none was considered resistant to the drug (resistant= PD while on Irinotecan treatment). The most common sites of disease were liver in 78%, lymph nodes in 28% and lung in 55% of patients. Response, according to RECIST criteria, has been assessed in the first 6 patients. There were 1 PR, 3 SD (1 lasting 5 months) and 2 PD. After dose reduction, toxicity has been acceptable with only 1 case of G4 ANC lasting 1 day, PLT G1, and delayed recovery of ANC≥1500 in 27 cycles. Conclusion: Administration of gimatecan po at doses that are well tolerated has been achieved and activity in metastatic colorectal carcinoma has been observed. The study is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sigma-Tau S.p.A. Sigma-Tau SpA
Identification of AGR3 as a potential biomarker though public genomic data analysis of triple-negative (TN) versus triple-positive (TP) breast cancer (BC).
Authors: Anita Umesh, Jenny Park, James Shima, Joseph Delaney, Robert Wisotzkey, Erin Kelly, Elizabeth Beatrice Chiu, Jyoti Madhusoodanan, Mamatha Shekar, Ilya Kupershmidt
Journal: Journal of Clinical Oncology (2012)

31 Background: TNBCs have an aggressive clinical phenotype with worse prognosis than TPBC. Here we sought to identify other genomic changes in patients with TN vs. TPBC, by mining TCGA breast cancer genomic data using the NextBio Clinical platform. Methods: Breast cancer patients with decreased (n=51) and increased (n=46) ER/PR/HER2 mRNA levels were selected with the molecular filter in NB Clinical. Top-ranked differentially expressed genes were identified then analyzed via NB Research, which comprises a library of individually curated publically available research and clinical grade genomic data. Results: Whole transcriptome analysis of TNBC and TPBC patients identified anterior gradient-3 (AGR3), a protein disulfide isomerase, as most downregulated (TNBC vs. TPBC, fold change = -178.2, p=2.7E-32). AGR3 mRNA was reduced in 94% of TNBC and increased in 96% of TPBC patients. AGR3 was hypomethylated in 50% of TPBC vs. 4% of TNBC patients, suggesting regulation by methylation. When the entire breast cancer cohort was stratified by AGR3 expression, underexpression was prevalent in younger patients (&lt;50 yr, 39%) compared to those with overexpression (&lt;50 yr, 23%). Further, 63% of AGR3 underexpressing patients had severe TP53 mutations vs. 19% with AGR3 overexpression. Breast cancer was most correlated to AGR3 in the NextBio Disease Atlas, with supporting data from 110 studies. AGR3 expression was decreased in ER- vs. ER+, PR- vs. PR+, HER2- vs. HER2+, and G3 vs. G1 tumors, and AGR3 promoter was hypermethylated in ER- vs. ER+, consistent with the TCGA results. Body Atlas showed strongest AGR3 expression in mucosa, fallopian tube, breast, and epithelial cells, in line with its proposed role in epithelial barrier function. Knockdown Atlas results showed TP53 mutation associated with reduced AGR3 mRNA, and the PharmacoAtlas showed positive regulation of AGR3 by estrogen analogues. Conclusions: Using the NextBio Clinical and Research platforms, we identified AGR3 as a marker of TNBC vs. TPBC that correlates with TP53 mutation status. AGR3 may provide an alternate route of TNBC treatment. Its potential in regulating epithelial barrier function may provide insights into the mechanism of disease progression.
Linac-stereotactic radiosurgery (LSRS) in the management of trigeminal neuralgia
Authors: S. Gurley, R. Mark, P. J. Anderson, T. Neumann, M. Nair
Journal: Journal of Clinical Oncology (2006)

18603 Background: Stereotactic Radiosurgery (SRS) with the Gamma Knife (GK) has been used successfully in the treatment of Trigeminal Neuralgia (TN). Results have been comparable to open surgery. There have been few reports with the use of LSRS in the management of TN. We report our updated results with LSRS in the treatment of TN. Methods: Between 2000 and 2006, 37 patients with medically refractory TN were treated with LSRS. Prior neurosurgical intervention had been performed in 28 patients. Ten patients had one procedure, 10 patients two, and 3 patients three interventions. All patients had typical TN. LSRS was given to the cranial nerve V entry root zone into the brainstem. Targeting was defined by CT and MRI Scans, and CT Cisternogram, utilizing axial, coronal, and sagittal images. Treatment planning was accomplished thru the Radionics Treatment Planning System. The dose was 87 Gy to D m , in one fraction using the 5 mm collimator and 6 arcs with the 20% Isodose line just touching the brainstem. This dosimetry is similar to Gamma Knife. The dose rate was 400 MU/min. Average Arc length was 130 degrees. Response to treatment was defined as excellent (no pain, off analgesics), good (no pain, with analgesics), and poor (continued pain despite analgesics). Results: With a median follow-up of 40 months (range 6–72 months), 73% (27/37) of patients have reported an excellent or good result after LSRS. One patient has sustained permanent ipsilateral facial numbness. Conclusions: LSRS offers comparable results to Gamma Knife SRS, with respect to both pain relief and complications, in the management of TN. No significant financial relationships to disclose.
Success rate and myeloid toxicity of carboplatin desensitization protocol in low grade glioma patients
Authors: S. Berrak, D. B. Beker, C. Canpolat, F. B. Cakir
Journal: Journal of Clinical Oncology (2007)

20012 The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low grade glial tumors is well established. This study was retrospectively designed to investigate the success rate and myeloid toxicity of carboplatin desensitization in a group of patients with carboplatin allergy. A total of 45 patients followed between October 1998-January 2007 with low grade glial tumors were included into study. Patients with severe hypersensitivity reactions (including anaphylaxis) were given 6-step desensitization protocol with gradual increase in concentration of carboplatin over 6 hours. Weekly absolute neutrophil count (ANC) and number of febrile neutropenia episodes of each patient during treatment period were collected from patient files. Among 45 patients, eight were switched to desensitization protocol. They had received a median of 6 courses (range 1–29) of carboplatin before developing their first allergic reaction. A median number of 15 courses of desensitizations (range 3–40) were given to these patients. Desensitization was successful in 6 patients. Age, gender, diagnosis were found to be similar in patients with and without carboplatin allergy. Regarding myeloid toxicity, mean percentage of follow-up weeks with ANC values below 1,500/mm3 in patients with and without desensitization were 0.42±0.04 and 0.21±0.02, respectively (p=0.009). Mean percentage of weeks with ANC values below 500/mm3 were not significant between two groups (p=0.28). However, desensitization protocol was not found to have an impact on number and presence of febrile neutropenia episodes. In conclusion, desensitization protocol might be an alternative to complete scheduled treatment in low grade glioma patients with hypersensitivity to carboplatin. Although, the percentage of low ANC weeks seemed to be statistically higher, insignificance of febrile neutopenia episodes in our patients demonstrated safety of desensitization protocol in terms of myeloid toxicity. No significant financial relationships to disclose.
Characteristics and risk factors of cisplatin induced ototoxicity in testicular cancer patients, detected by distortion product otoacustic emmision (DPOAE)
Authors: K. Biro, L. Noszek, P. Prekopp, K. Nagyiványi, L. Géczi, I. Gaudi, I. Bodrogi
Journal: Journal of Clinical Oncology (2005)

4578 Background: Cisplatin based chemotherapy results in high cure rate in testicular cancer. The issue of toxicity is of special concern in young men with a probability of cure of at least 70–80% even in disseminated disease. We studied the characteristics and risk factors of long-term ototoxic effect of cisplatin, by measuring DPOAE, which is a highly sensitive new method for detecting high frequency hearing loss. Methods: 221 patients with median follow up time of 4.27 years and a median age of 37 yrs were assessed by DPOAE. 100mg/m2 cisplatin were administered per cycle, in EP, BEP, VeIP, VIP or VPB regimens. The control group consisted of 40 testicular cancer patients without chemotherapy. A detailed medical history evaluated audiological risk factors, and hearing complaints. DPOAE was measured in 8 frequencies from 750Hz to 8000Hz. Paired t-test, and one-way analysis of variance was used for statistical evaluation. Results: Symptomatic ototoxicity was observed in 21% of patients. Below 400mg/m2 no amplitude changes were detected. Beyond this dose hearing impairment proved to be dose-dependent, bilateral and permanent. Contrary to the literature not only high frequencies were affected. In patients receiving higher doses than 400mg/m2 progressively extended towards lower frequencies that are important for speech perception. At 400mg/m2 and 500mg/m2 significant amplitude change was detected at 2000Hz (p=0.02 and 0.008) and at 600mg/m2 significant amplitude change was detected at 1500Hz (p=0.01). The only statistically significant risk factor was cumulative dose of cisplatin; neither smoking nor noise exposure were independent risk factors. Conclusion: DPOAE is a fast, noninvasive, and reliable method in detecting late ototoxicity in testicular cancer patients. In our study high frequency hearing loss correlated with the cumulative dose of cisplatin. Hearing impairment contributes to the already compromised situation of cancer patient. No significant financial relationships to disclose.
Radiation Recall Dermatitis From High-Dose Interferon Alfa-2b
Authors: Rosalyn Thomas, Baldassarre Stea
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.1.355 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11773198 Radiation Recall Dermatitis From High-Dose Interferon Alfa-2b Rosalyn ThomasxRosalyn ThomasSearch for articles by this author , Baldassarre SteaxBaldassarre SteaSearch for articles by this author Show More University of Arizona Health Science Center, Tucson, AZ https://doi.org/10.1200/JCO.2002.20.1.355 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Assessing adherence to the American College of Chest Physicians’ (ACCP) recommendations for thromboprophylaxis in hospitalized cancer patients
Authors: A. N. Amin, S. A. Stemkowski, J. Lin, G. Yang
Journal: Journal of Clinical Oncology (2007)

9047 Background: This study evaluates whether clinicians are providing appropriate VTE prophylaxis to at-risk surgical and non- surgical cancer patients in accordance with ACCP guidelines. Methods: Premier's inpatient administrative data were used to assess VTE prophylaxis rates in fourteen cancer types. Patients age 40 or older, with a minimum length of stay of six days, and no contraindications for anti-coagulation were included in the study. Two rates were determined; the rate of discharges receiving any level of anticoagulation and the rate of patients receiving appropriate prophylaxis by comparing daily use of anti-coagulants and compression devices, dosage, and prophylaxis duration with ACCP recommendations. The 6 th guidelines were used due to their release prior to the study period. Rates based on the 7 th guidelines were calculated for the same patient cohort to assess how the revised guidelines affect our findings. Trends were assessed by comparing prophylaxis rates by quarter. Results: 72,391 discharges from 225 hospitals between January 2002 and September 2005 met the inclusion criteria. 29% of all at-risk cancer discharges received the recommended prophylaxis regimen. Rates varied by cancer type ranging from 18.7% in prostate to 36.3% in colorectal cancer discharges. 55% did not receive any anti-coagulation prophylaxis, 9.5% received insufficient dosage and 5.8% did not receive prophylaxis for the appropriate duration. The appropriate VTE prophylaxis rate is higher for surgical cancer than for non-surgical cancer discharges (32.3% vs. 27.7%). Trends suggest a slight increase in appropriate prophylaxis rates for all types of cancer discharges. Appropriate prophylaxis rates based on 7 th guidelines are lower than rates based on the 6 th guidelines due to the more specific recommendation in the 7 th guidelines. Conclusions: Cancer patients are known to have significant risk for VTE, yet VTE prophylaxis for at-risk non-surgical cancer patients in hospitals is not optimal. Rates for surgical cancer patients were only slightly higher. Using the 7 th recommendations results in lower prophylaxis rates. More effort is required to increase awareness of the ACCP recommendations for thromboprophylaxis in cancer patients. No significant financial relationships to disclose.